The prophylactic effect of co-enzyme Q10 versus placebo on contrast-induced nephropathy in patients with diabetes mellitus type II

The prophylactic effect of co-enzyme Q10 versus placebo on contrast-induced nephropathy in patients with diabetes mellitus type II: a double-blind randomized clinical trial study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N337

Enrollment

104

Registered

2020-01-29

Start date

2020-02-20

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus with nephropathy. Diabetes mellitus due to underlying condition with diabetic nephropathy

Interventions

Intervention 1: Intervention group: Coenzyme Q10 100 mg capsule (manufactured by Hakiman Teb Pharmaceutical Company) daily one day before angiography until 6 days after. Intervention 2: Control group:

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 65 years, Diabetes mellitus type II for at least one year, Need for CT scan with contrast material, Microalbuminuria or macroalbuminuria

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding, Receiving contrast material last week, Taking antioxidants last week, Kidney activity instability, Sensitivity to iodinated contrast agents

Design outcomes

Primary

Measure	Time frame
Serum creatinine. Timepoint: Daily before the intervention and 7 days after that. Method of measurement: By laboratory test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAshkan Karbasi

Hamedan University of Medical Sciences

akarbasi@gmx.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026